Arteriocyte is now a part of Isto Biologics.

News + Views

Blog

ISTO Technologies to Present at Windhover In3 Medical Device Summit

May 30, 2006

May 30, 2006 (St. Louis, MO) – ISTO Technologies, Inc., announced today that the Company’s President and Chief Executive Officer, Dr. Mitchell Seyedin will give a corporate presentation at the In3 Medical Device Summit Conference, Thursday, June 22, 2006 at 11:00 am PT. The conference will be held at The Palace Hotel in San Francisco, CA from June 21-23, 2006. MedTech Insight, a division of Windhover Information, Inc., is sponsor of the conference.

“ISTO’s differentiated technology uses juvenile cartilage cells, also known as chondrocytes. These cells inherently have an enhanced capacity for regeneration and repair over cells isolated from adult cartilage, thus offering a strong potential for clinical success,” said Mitchell Seyedin Ph.D., President and Chief Executive Officer of ISTO.

Cartilage works as a “shock absorber” to protect all joints including spinal discs from wear and tear experienced during motion. Injuries to adult cartilage undergo only limited healing without treatment. Degradation of cartilage in joints and spinal discs often leads to irreversible damage, causing pain and disability. Osteoarthritis and spinal back pain are the two most common causes of disability in the United States.

The Company’s versatile, cell-based product pipeline includes Neocartilage, a manufactured scaffold-free live cartilage graft grown from juvenile chondrocytes. The Neocartilage graft is designed to repair and restore joint function in the knee. NuQu™, a cell-based injectable formulation of juvenile chondrocytes in development, is designed for nucleus regeneration in the spine. NuQu offers a potential therapeutic solution for early intervention of disc degeneration. InQu™, a synthetic biomaterial, is projected to be the Company’s first-to-market product. It is a hybrid scaffold of synthetic and biologic polymers. Pre-clinical data has demonstrated that InQu effectively promotes bone and cartilage regeneration.

“We are delighted for the opportunity to present ISTO’s progress at Medtech Insight, since it coincides with the initiation of our next round of financing,” adds Dr. Seyedin.

About ISTO Technologies, Inc.
ISTO Technologies, Inc. is an orthobiologic company focused on developing differentiated products for sports medicine and spinal therapy. ISTO’s orthobiologic products are intended to repair and regenerate damaged cartilage tissue in knee joints and spinal discs. For additional information on ISTO, please visit our website at www.istobiologics.com, or contact us at 314-995-6049 or by email at info@istotech.com.

To top